CanSense is developing an accurate, fast, non-invasive, blood diagnostic for the early detection of Cancer using Spectroscopy and AI-based technologies. Our first test is focussed on Bowel Cancer.
0% of minimum goal raised
Minimum Target £ 250,000 |
Minimum investment amount £ 10,000 |
Maximum Target £ 1,000,000 |
Maximum investment amount £ 1,000,000 |
Cansense Ltd is a start-up life sciences company focused on developing blood-based assays that meet the need for accurate, fast, inexpensive and scalable tests for detecting cancer using technology that has platform potential. Our initial development is targeted towards the detection of bowel cancer or colorectal cancer (CRC) using a non-invasive test that can be widely used in primary care. Additional cancers have been identified to maximise the utility and commercial potential. CanSense Group is an award-winning university spin-out company. Its experts demonstrate the required clinical, academic, innovation and business acumen to deliver tests that will transform patient outcomes.
CanSense's CEO Adam Bryant pitching at one of Angels Den's events. Please see full Q&A here: https://docs.google.com/document/d/1wGYUx17B4f17NwJLeCAqz7iXrTLvfm2yGGFhbORI03E/edit?usp=sharing
Interview with CanSense's CEO Adam Bryant
CanSense is developing an innovative healthcare technological solution to address the significant health care need for early detection of cancers including Bowel or Colorectal Cancer (CRC).
CanSense-CRC diagnostic has achieved sensitivity 84%; specificity 91% for early detection of CRC and can detect pre-malignant changes at an easily treatable stage (polyps ~2mm) with high accuracy, 84.2% sensitivity & 89.5% specificity.
Our detection platform has applications in primary care assessment of their symptomatic patients, asymptomatic screening and for early detection of cancer recurrence.
The test can interrogate for other cancer types offering a true diagnostic platform solution.
Colorectal cancer (CRC) is the third commonest cancer globally with the burden expected to increase to 2.2M new cases by 2030, particularly in the young. Early diagnosis is crucial to reduce mortality rates yet 60% of patients present at advanced stages (III/IV), giving the UK some of the worst colorectal cancer outcomes in Europe.
Lack of access to diagnostics during the COVID-19 pandemic has further worsened cancer survival figures. This highlights the need for accessible cancer testing at primary care level to avoid delayed detection.
We need to re-think diagnostics - addressing the problems of late stage diagnosis, long delays for referral, capacity constraints and cost.
The global addressable non-invasive colorectal diagnostics market is $1.03B (CAGR 5.3%) est. $2.2B by 2030 (GlobalData). The global economic costs associated with negative colonoscopy is at least $4.2B pa ($370M in the UK). Market analysis ($50 per CanSense-CRC test) results in a global healthcare saving of $3.8B pa ($335M in UK).
We have developed a robust business model having worked with multiple prestigious Business Accelerators.
Interviewed >200 customers: Identifying our early adopters as pharmaceutical clinical trials and private/public primary healthcare providers.
Direct fee-for-service model through a centralised laboratory leading to an integrated healthcare provision.
CanSense is developing an innovative healthcare technological solution to address the significant health care need for early detection of cancers including Bowel or Colorectal Cancer (CRC).
CanSense-CRC diagnostic has achieved sensitivity 84%; specificity 91% for early detection of CRC and can detect pre-malignant changes at an easily treatable stage (polyps ~2mm) with high accuracy, 84.2% sensitivity & 89.5% specificity.
Our detection platform has applications in primary care assessment of their symptomatic patients, asymptomatic screening and for early detection of cancer recurrence.
The test can interrogate for other cancer types offering a true diagnostic platform solution.
Colorectal cancer (CRC) is the third commonest cancer globally with the burden expected to increase to 2.2M new cases by 2030, particularly in the young. Early diagnosis is crucial to reduce mortality rates yet 60% of patients present at advanced stages (III/IV), giving the UK some of the worst colorectal cancer outcomes in Europe.
Lack of access to diagnostics during the COVID-19 pandemic has further worsened cancer survival figures. This highlights the need for accessible cancer testing at primary care level to avoid delayed detection.
We need to re-think diagnostics - addressing the problems of late stage diagnosis, long delays for referral, capacity constraints and cost.
The global addressable non-invasive colorectal diagnostics market is $1.03B (CAGR 5.3%) est. $2.2B by 2030 (GlobalData). The global economic costs associated with negative colonoscopy is at least $4.2B pa ($370M in the UK). Market analysis ($50 per CanSense-CRC test) results in a global healthcare saving of $3.8B pa ($335M in UK).
We have developed a robust business model having worked with multiple prestigious Business Accelerators.
Interviewed >200 customers: Identifying our early adopters as pharmaceutical clinical trials and private/public primary healthcare providers.
Direct fee-for-service model through a centralised laboratory leading to an integrated healthcare provision.